The use of an IGF-1R inhibitor and of chemotherapeutic substances in refractory tumors is being proven in numerous trials [149,150,151,152] and could represent an interesting new therapeutic approach for DLBCL via their action on the YAP system. The gene discussed is IGF1R; the disease is diffuse large B-cell lymphoma.